Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Developmental Medicine and Child Neurology
|
February 10, 2025
Reproducibility of the Motor Optimality Score-Revised in infants with an increased risk of adverse neurodevelopmental outcomes
Carly Luke, Arend F Bos, Michelle Jackman, et al.
Therapeutic Advances in Infectious Disease
|
January 5, 2023
Improving care for individuals with serious infections who inject drugs
Colleen Kershaw, Jon D Lurie, Charles Brackett, et al.
BMC Neurology
|
June 14, 2013
Australian Cerebral Palsy Child Study: protocol of a prospective population based study of motor and brain development of preschool aged children with cerebral palsy
Roslyn N Boyd, Rachel Jordan, Laura Pareezer, et al.
Surgical Oncology
|
November 27, 2022
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
James V Pellicane, Peter D Beitsch, David T Rock, et al.
JCO Precision Oncology
|
September 15, 2022
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
Pat W Whitworth, Peter D Beitsch, Mary K Murray, et al.
BMJ Open
|
July 15, 2017
PREDICT-CP: study protocol of implementation of comprehensive surveillance to predict outcomes for school-aged children with cerebral palsy
Roslyn N Boyd, Peter Sw Davies, Jenny Ziviani, et al.
Annals of Surgical Oncology
|
April 5, 2022
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
Pat Whitworth, Peter D Beitsch, James V Pellicane, et al.
JCO Precision Oncology
|
April 27, 2022
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature
Pat W Whitworth, Peter D Beitsch, James V Pellicane, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Developmental Medicine and Child Neurology
|
February 10, 2025
Reproducibility of the Motor Optimality Score-Revised in infants with an increased risk of adverse neurodevelopmental outcomes
Carly Luke, Arend F Bos, Michelle Jackman, et al.
Therapeutic Advances in Infectious Disease
|
January 5, 2023
Improving care for individuals with serious infections who inject drugs
Colleen Kershaw, Jon D Lurie, Charles Brackett, et al.
BMC Neurology
|
June 14, 2013
Australian Cerebral Palsy Child Study: protocol of a prospective population based study of motor and brain development of preschool aged children with cerebral palsy
Roslyn N Boyd, Rachel Jordan, Laura Pareezer, et al.
Surgical Oncology
|
November 27, 2022
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
James V Pellicane, Peter D Beitsch, David T Rock, et al.
JCO Precision Oncology
|
September 15, 2022
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
Pat W Whitworth, Peter D Beitsch, Mary K Murray, et al.
BMJ Open
|
July 15, 2017
PREDICT-CP: study protocol of implementation of comprehensive surveillance to predict outcomes for school-aged children with cerebral palsy
Roslyn N Boyd, Peter Sw Davies, Jenny Ziviani, et al.
Annals of Surgical Oncology
|
April 5, 2022
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
Pat Whitworth, Peter D Beitsch, James V Pellicane, et al.
JCO Precision Oncology
|
April 27, 2022
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature
Pat W Whitworth, Peter D Beitsch, James V Pellicane, et al.
Page
of 2